Study identification

EU PAS number

EUPAS35860

Study ID

35861

Official title and acronym

The PsoProtect Research Database (Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of Covid-19 infecTion)

DARWIN EU® study

No

Study countries

Argentina
Australia
Austria
Belgium
Brazil
Canada
Chile
Colombia
France
Germany
India
Iran, Islamic Republic of
Italy
Luxembourg
Malaysia
Mauritius
Netherlands
Norway
Peru
Philippines
Poland
Spain
Sweden
Thailand
Türkiye
United Arab Emirates
United Kingdom
United States

Study description

PsoProtect (Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of Covid-19 infecTion) is an international registry for reporting outcomes of COVID-19 in individuals with psoriasis and related IMIDs (rheumatic diseases and atopic dermatitis). By collecting observational data on cases of COVID-19 in psoriasis and related IMIDs on a global scale, PsoProtect has the potential to rapidly improve our understanding of how factors such as systemic immunomodulator/immunosuppressant therapies, comorbidities and demographic variables including age, sex and ethnicity affect outcomes of COVID-19 in IMIDs, for the benefit of the international clinical community.PsoProtect is closely aligned with recently established partner databases for clinician-reported outcomes to COVID-19 in other IMIDs (such as www.coviibd.org and www.rheum-covid.org). We will continue to collaborate closely with these research teams in order to facilitate valuable cross-disease analyses. The primary objective is to uncover the underlying determinants of the outcome of COVID-19 in psoriasis and the related IMIDs rheumatic diseases and atopic dermatitis. Specifically, we will determine the impact of immunomodulator/immunosuppressant therapies, comorbidities and demographic variables such as age, sex and ethnicity on outcomes of COVID-19 in IMIDs.The secondary objectives are to determine the impact of COVID-19 on the disease course/severity of psoriasis and related IMIDs (rheumatic diseases and atopic dermatitis), and to determine the impact and outcomes of COVID-19 across diseases and therapies, and create a data resource to enrich other allied datasets through cross-disease collaboration.This is an observational cohort study of outcomes to COVID-19 in psoriasis and related IMIDs. Real-world observational clinical data is collected using the web-based clinician and patient facing PsoProtect case report forms (designed using the REDCap platform).

Study status

Planned
Research institutions and networks

Institutions

Contact details

Satveer Mahil

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, The Psoriasis Association (UK)
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable